{"filing":{"accession_number":"0001628280-26-049426","cik":"0001708599","ticker":"SER","company_name":"Serina Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"ser-20260719.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708599/000162828026049426/ser-20260719.htm"},"events":[{"id":20159,"run_id":18147,"accession_number":"0001628280-26-049426","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on an Amended and Restated Employment Agreement with CEO Steve Ledger that modifies his compensatory arrangements, including base salary ($500,000), target bonus (50% of base), equity awards, and severance/change-of-control provisions. While the agreement amends an existing employment contract, the principal disclosed action is the modification of executive compensation terms, severance multiples, and equity vesting provisions—all hallmarks of exec_compensation rather than appointment or departure.","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19456,"accession_number":"0001628280-26-049426","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on an Amended and Restated Employment Agreement with CEO Steve Ledger that modifies his compensatory arrangements, including base salary ($500,000), target bonus (50% of base), equity awards, and severance/change-of-control provisions. While the agreement amends an existing employment contract, the principal disclosed action is the modification of executive compensation terms, severance multiples, and equity vesting provisions—all hallmarks of exec_compensation rather than appointment or departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:52:36.242442+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19456,"accession_number":"0001628280-26-049426","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on an Amended and Restated Employment Agreement with CEO Steve Ledger that modifies his compensatory arrangements, including base salary ($500,000), target bonus (50% of base), equity awards, and severance/change-of-control provisions. While the agreement amends an existing employment contract, the principal disclosed action is the modification of executive compensation terms, severance multiples, and equity vesting provisions—all hallmarks of exec_compensation rather than appointment or departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:52:36.242442+00:00","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-07-23"}]}